The FDA approved Ultomiris (ravulizumab) injection for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease.
FDA approves new treatment for adult patients with rare, life-threatening blood disease
More from FDA News AlertsMore posts in FDA News Alerts »
- FDA Takes Steps to Increase Availability of COVID-19 Vaccine
- Coronavirus (COVID-19) Update: June 11, 2021
- Viona Pharmaceuticals Inc., Issues Voluntary Nationwide Recall of Metformin HCl Extended-Release Tablets, USP 750 mg, Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity
- Innova Medical Group Recalls Unauthorized SARS-CoV-2 Antigen Rapid Qualitative Test with Risk of False Test Results